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Background: The implications of the menstrual cycle for disease susceptibility, 
development, and severity of acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) infection are largely unknown. 
Case presentation: Here we describe two women infected with SARS-CoV-2 
whose RT-PCR test results and symptoms changed during the menstrual cycle. 
The first patient developed a fever on the first day of her menstrual period, and 
again on the first day of her next menstrual period after hospital discharge. 
RT-PCR test results were positive during the first menstrual period before 
admission, but turned negative during hospitalization, and then were positive 
again during the second menstrual period after hospital discharge. Another one 
also developed a fever again on the first day of her menstrual period after hospital 
discharge. RT-PCR test results were negative before admission and during 
hospitalization, but turned positive during the first menstrual period after hospital 
discharge.  
Conclusions: The cases indicate sex hormones may play an important role in 
SARS-CoV-2 infection. For women with history of exposure to SARS-CoV-2, the 
management protocol should include assessment of the menstrual status. 
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The 2019 novel coronavirus infection (COVID-19), caused by severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged as a major 
global health threat since December 2019 1-4. As of June 27, 2020, the pandemic 
had registered 9,473,214 cases and 484,249 deaths worldwide 5. A population 
level observational study by Sun and colleagues 6 revealed that a sharp increase of 
COVID-19 was reported among people aged between 30 and 50 years, and 40% 
of the patients were female, indicates women of childbearing age are at high risk 
of infection. Growing evidences indicate that female immunity changes over the 
menstrual cycle 7,8. However, the implications of the menstrual cycle for disease 
susceptibility, development, and severity of COVID-19 are largely unknown. 
Here, we report the epidemiologic and clinical features of two female individuals 




A 37-year-old, previously healthy (gravida 2, para 2, regular menstrual cycle, no 
history of hormonal therapies), woman had dinner with her relative on January 12, 
2020. Five days later, her relative had a fever and was confirmed to be infected 
 











with SARS-CoV-2. The woman had no fever or any other gastrointestinal or 
respiratory symptoms until January 28, 2020, the first day of her menstrual period 
(Figure 1A). At first, she had only a slight and intermittent fever. However, the 
next day afternoon, she developed high fever, tiredness, and lack of appetite. 
Because of the possibility of infection with SARS-CoV-2, she was prescribed 
ibuprofen, oseltamivir (75 mg every 12 h orally), arbidol (0.2 g every 8 h orally), 
and moxifloxacin (0.4 g every day orally) by a community physician. Lopinavir 
and Ritonavir tablets (200 mg/50 mg every 12 h orally) were added to her antiviral 
regimen two days later. Her symptoms did not improve, which prompted her to 
come to the emergency department on February 2, 2020. Although chest 
auscultation was normal, chest CT scans showed bilateral lower lobe infiltrates 
(Figure 2A). Real-time reverse transcriptase–polymerase chain reaction (RT-PCR) 
test for nucleic acid of SARS-CoV-2 on an oropharyngeal swab was performed as 
described in a previous study 2. The same technician and brand of test kit (Novel 
Coronavirus PCR Fluorescence Diagnostic Kit, BioGerm Medical 
Biotechnology), which was recommended by the Chinese Center for Disease 
Control and Prevention, was used in this report. The result of RT-PCR test was 
positive. The patient was asked to self-quarantine at home because of the limited 
number of hospital beds in Wuhan at that time. Her temperature dropped to 
normal one day later, the last day of her menstrual period.  
 











On February 4, 2020, the patient was hospitalized with COVID-19. On 
admission, the physical examination revealed body temperature of 97.5℉(36.4℃
), blood pressure of 98/61 mmHg, pulse rate of 78 beats per minute, respiratory 
rate of 20 breaths per minute and oxygen saturation of 95% on room air. The 
results of her laboratory testing showed a C-reactive protein count 12.3 mg/L (< 1 
mg/L indicates low risk of cardiovascular disease; 1 - 3 mg/L indicates medium 
risk of cardiovascular disease; > 3 mg/L indicates high risk of cardiovascular 
disease; > 10 mg/L indicates infection or inflammation) and erythrocyte 
sedimentation rate of 30 mm/H (normal range 10 - 30 mm/H). Other pertinent 
laboratory tests, including complete blood count, coagulation tests, liver function 
tests, kidney function tests, metabolic panel tests, and high-sensitivity cardiac 
troponin tests did not reveal any clinically significant results. A follow-up chest 
CT scan on February 8, 2020, showed the shadow on bilateral lung was partly 
absorbed (Figure 2B). Thus, all of her antiviral and antibacterial medications were 
canceled. RT-PCR tests for nucleic acid of SARS-CoV-2 on oropharyngeal swabs 
were performed 3 and 6 days after admission and the results were positive. The 
RT-PCR tests on oropharyngeal swabs were repeated 10 and 12 days after 
admission, and both showed negative results. On February 14, 2020, a repeated 
chest CT scan showed a further improvement of ground-glass opacification 
(Figure 2C). Her temperature remained normal during hospitalization. According 
to the criteria for hospital discharge in China including: (1) normal temperature 
 











for at least 3 days, (2) resolution of respiratory symptoms, (3) substantially 
improved radiological signs, and (4) negative results in two consecutive RT-PCR 
tests performed ≥ 24 h apart, this patient was discharged on February 18, 2020. 
After hospital discharge, the patient was asked to continue home quarantine 
for 14 days. She felt well until February 24, 2020, the first day of her menstrual 
period. The patient did not report contact with any other person but had fever 
again, peaking at 100.2℉(37.9℃). Except for tiredness, she had no other 
symptoms at that same time. She took arbidol (0.2 g every 8 h orally) and 
moxifloxacin (0.4 g every day orally) for three days. The results of a RT-PCR test 
on February 25, 2020 and a repeated test on oropharyngeal swabs four days later 
were both positive. However, chest CT scans showed no changes from the 
previous results (Figure 2D). The patient still had a slight and intermittent fever 
until February 29, 2020, the last day of her menstrual period. Since then, her 
temperature had remained normal. The RT-PCR test on oropharyngeal swab was 
performed on March 10, 2020, and the result was negative. However, her blood 
was positive for both IgG and IgM antibodies (YHLO-CLIA-IgG, 
















A 44-year-old, previously healthy (gravida 1, para 1, regular menstrual cycle, no 
history of hormonal therapies), woman was working as a nurse in a hospital in 
Wuhan, China. On January 24, she began to have a slight fever, peaking at 100.4 
℉(38 ℃) at night (Figure 1B). Because of the possibility of infection with 
SARS-CoV-2 due to occupational contact history, she was prescribed arbidol (0.2 
g every 8 h orally) by a physician. On January 26, 2020, the first day of her 
menstrual period, she developed tiredness, muscle soreness, palpitation, and lack 
of appetite. She continued taking arbidol during the menstrual period, but the 
symptoms did not improve. On February 2, the patient went to outpatient 
department in a hospital. Chest CT scans showed multiple infiltration in the 
bilateral lung view (Figure 2E). Blood examination showed a white blood cell 
count 3.88 * 10 ^ 9 / L and lymphocyte count 0.94 * 10 ^ 9 / L. Although the 
result of RT-PCR test on an oropharyngeal swab was negative, the woman was 
diagnosed with COVID-19 based on the occupational exposure history, symptoms 
and chest CT results.  
On February 3, 2020, the patient was hospitalized with COVID-19. On 
admission, the physical examination revealed body temperature of 99.5℉(37.5℃
), blood pressure of 105/85 mmHg, pulse rate of 110 beats per minute, respiratory 
rate of 20 breaths per minute and oxygen saturation of 94% on room air. The 
 











results of her laboratory testing showed a C-reactive protein count 14.8 mg/L and 
erythrocyte sedimentation rate of 40 mm/H. The serum-specific IgM antibodies to 
eight respiratory pathogens (IgM detection kit for respiratory pathogens, 
EUROIMMUN Co. Ltd Beijing, China), including respiratory syncytial virus, 
adenovirus, type A and type B influenza virus, parainfluenza virus, Legionella 
pneumophila, Mycoplasma pneumonia and Chlamydia pneumonia, were detected 
negative. Her temperature returned to normal on the next day after her admission. 
Thus, all of her antibacterial medications were canceled. A follow-up chest CT 
scan on February 8, 2020, showed decreased infiltration in both left and right 
lungs (Figure 2F). RT-PCR tests for nucleic acid of SARS-CoV-2 on 
oropharyngeal swabs were performed 3, 7, 9 and 11 days after admission and the 
results were negative. On February 14, 2020, a repeated chest CT scan showed a 
significant improvement of infiltration in all lesions (Figure 2G). Her temperature 
remained normal during hospitalization.  
After hospital discharge on February 18, 2020, the patient was asked to 
continue home quarantine for 14 days. She felt well until February 21, 2020, the 
first day of her menstrual period. She had fever again with tiredness and dizziness, 
peaking at 99.3℉(37.4℃). She took arbidol (0.2 g every 8 h orally) and 
moxifloxacin (0.4 g every day orally) for five days. The results of a RT-PCR test 
for nucleic acid of SARS-CoV-2 on oropharyngeal swabs on February 23, 2020 
 











was positive. Her blood was also positive for both IgG and IgM antibodies against 
SARS-CoV-2 (YHLO-CLIA-IgG, YHLO-CLIA-IgM kits, YHLO Biotech Co. Ltd 
Shenzhen, China). However, chest CT scans did not show any sign of increased 
infiltration (Figure 2H). The patient still had a slight and intermittent fever until 
February 25, 2020, the day before the last day of her menstrual period. Since then, 
her temperature had remained normal. The RT-PCR test on oropharyngeal swab 
was performed on February 28, 2020, the results were negative.  
Discussion and conclusions 
There are reported sex differences in the susceptibility and outcomes of infectious 
disease 9,10. A recent epidemiological study of the COVID-19 outbreak shows that 
SARS-CoV-2 might have a longer incubation period and less pronounced 
symptoms in women than in men 11. However, the mechanism underlying these 
differences remains unclear. Here, we report two women infected with 
SARS-CoV-2 whose RT-PCR test results and symptoms changed during the 
menstrual cycle. The first patient developed a fever on the first day of her 
menstrual period, and again on the first day of her next menstrual period after 
hospital discharge. RT-PCR test results were positive during the first menstrual 
period before admission, turned negative during hospitalization, and then positive 
again during the second menstrual period, which occurred after hospital discharge. 
Another patient also developed a fever again on the first day of her menstrual 
period after hospital discharge. RT-PCR test results were negative before 
 











admission and during hospitalization, but turned positive during the first 
menstrual period after hospital discharge. These cases indicate sex hormones may 
play an important role in SARS-CoV-2 infection. 
In female humans, the levels of sex hormones, largely estrogens and 
progesterone, vary during the menstrual cycle and decrease sharply before 
menstruation 12. The dramatic fluctuation in sex hormone levels is associated with 
changes in immune function and response to respiratory virus infections 13. In an 
animal model of influenza A virus infection, estrogen is reported to be a potent 
anti-inflammatory hormone and to reduce adaptive immune responses and protect 
hosts from influenza A virus-mediated pathogenesis 14. In another animal model 
of the severe acute respiratory syndrome coronavirus (SARS-CoV) infection, 
treatment with an estrogen receptor antagonist or ovariectomy can increase 
mortality in females, indicating a critical role of estrogen receptor signaling in 
protecting females from severe SARS-CoV infection 15. Consistent with these 
previous studies, our findings in the current case showed a close association 
between symptoms, positive RT-PCR test results and the menstruation. This 
phenomenon might be partly explained by the findings of Sangappa et al. 16. They 
found that the expression of angiotensin converting enzyme 2 (ACE2), by which 
SARS-CoV-2 enters human cells, is high in human endometrial stroma and 
increases in the secretory phase. Furthermore, ACE2 expression in human 
endometrial stroma is promoted by progesterone. Future studies exploring the role 
 











and mechanism of sex hormones in the pathogenesis of SARS-CoV-2 infection 
are warranted. 
In the first case, fever occurred on the first day and disappeared on the last 
day of her menstrual period. In the second case, symptoms worsened when 
menstruation started. These observations suggest that the menstrual status needs to 
be included in the observation period. During the observation period, the 
identification of potentially infected patients should be based on the results of 
RT-PCR tests or CT scans rather than symptoms. 
The patients in this report had a recurrence of fever and positive RT-PCR test 
results during their first menstrual period after hospital discharge. Although the 
negative RT-PCR test results during hospitalization might be false-negative 17, 
there are increasing reports regarding positive RT-PCR test results among 
convalescent COVID-19 patients 18-20. These observations suggest that some of 
the recovered patients still might be virus carriers. The management protocol for 
hospital discharge might need to be reevaluated, and the 14 days of home 
quarantine should include assessment of the menstrual status of female patients.  
In summary, our report provides an initial view of the association between the 
menstrual cycle, symptoms and RT-PCR test results. Future studies in large 
cohorts are necessary to address the effect of sex hormones on the clinical course 
of COVID-19.  
 
 












COVID-19: the 2019 novel coronavirus infection; SARS-CoV-2: severe acute 
respiratory syndrome coronavirus 2; RT-PCR: Real-time reverse transcriptase–
polymerase chain reaction; SARS-CoV: severe acute respiratory syndrome 
coronavirus; ACE2: angiotensin converting enzyme 2 
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Figure Legends 
Figure 1. Timeline of changes of RT-PCR test results and symptoms during 
the menstrual cycle of cases infected with SARS-CoV-2. Case one (A). (A) 
Sixteen days after exposure to SARS-CoV-2, fever occurred on the first day of her 
menstrual period, and again on the first day of her next menstrual period after 
hospital discharge. RT-PCR test results were positive during the first menstrual 
period before admission, turned negative during hospitalization, and then positive 
again during the second menstrual period, which occurred after hospital discharge. 
Case two (B). (B) Fever occurred two days before her menstrual period, and again 
on the first day of her next menstrual period after hospital discharge. RT-PCR test 
results were negative before admission and during hospitalization, but turned 
positive during the first menstrual period after hospital discharge. RT-PCR 
indicates real time polymerase chain reaction test for the coronavirus disease 2019 
(COVID-19) nucleic acid. 
 

























Figure 2. Transverse chest CT images of cases infected with SARS-CoV-2. 
Case one (A-D). Representative images of the chest CT scans showing (A) 
bilateral ground-glass opacity and subsegmental areas of consolidation on day 6 
after symptom onset, (B) bilateral ground-glass opacity on day 12 after symptom 
onset, (C) bilateral patchy ground-glass opacity on day 18 after symptom onset, 
and (D) focal ground-glass opacity on day 29 after symptom onset. Case two 
(E-H). Representative images of the chest CT scans showing (E) multiple 
ground-glass opacity and consolidation shadow in the right upper lung lobe and 
left lower lung lobe on day 10 after symptom onset, (F) absorption of bilateral 
ground glass opacity on day 16 after symptom onset, (G) a significant absorption 
of the shadow in all lesions on day 22 after symptom onset, and (H) the shadow 
was absorbed almost completely on day 31 after symptom onset. 
 
